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Abstract
Introduction: People living with multiple long-term conditions (multimorbidity) (MLTC-M) experience an accumulating
combination of different symptoms. It has been suggested that these symptoms can be tracked longitudinally using
consumer technology, such as smartphones and wearable devices.
Aim: The aim of this study was to investigate longitudinal user engagement with a smartwatch application, collecting survey
questions and active tasks over 90 days, in people living with MLTC-M.
Methods: ‘Watch Your Steps’was a prospective observational study, administering multiple questions and active tasks over
90 days. Adults with more than one clinician-diagnosed long-term conditions were loaned Fossil® Sport smartwatches, pre-
loaded with the study app. Around 20 questions were prompted per day.
Daily completion rates were calculated to describe engagement patterns over time, and to explore how these varied by
patient characteristics and question type.
Results: Fifty three people with MLTC-M took part in the study. Around half were male ( = 26; 49%) and the majority had a
white ethnic background (n = 45; 85%). About a third of participants engaged with the smartwatch app nearly every day.
The overall completion rate of symptom questions was 45% inter-quartile range (IQR 23–67%) across all study participants.
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Older patients and those with greater MLTC-M were more engaged, although engagement was not significantly different
between genders.
Conclusion: It was feasible for people living with MLTC-M to report multiple symptoms per day over 3 months. User
engagement appeared as good as other mobile health studies that recruited people with single health conditions, despite the
higher daily data entry burden.
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Introduction
Multiple long-term conditions (multimorbidity) (MLTC-M)
is defined as having two or more long-term conditions at the
same time.1 In line with a rising MLTC-M prevalence
worldwide,2 the proportion of those aged over 65 with
MLTC-M in England is projected to increase from 54% in
2015 to 68% in 2035.3 One in three emergency hospital
admissions have five or more long-term conditions, up from
one in ten a decade ago.4 Multiple long-term conditions
(multimorbidity) reduces quality of life and increases the
likelihood of hospital admission, re-admissions and in-
creases overall healthcare costs.5,6
People living with MLTC-M have to deal with an ac-
cumulating combination of different symptoms – the se-
verity of which varies through time – plus the potential
harms of multiple treatments.7 Managing one health con-
dition can exacerbate another, and the dynamic nature of
symptoms makes it difficult to choose an optimal treat-
ment.8 Much research to date is cross-sectional rather than
longitudinal, making it impossible to study temporal
changes.1 Where longitudinal studies do exist, they often
measure disease change at widely spaced intervals.9–11
Consumer technology, such as smartphones and wearable
devices, has been identified as a potential way to track and
monitor longitudinal symptoms of people living with MLTC-
M.1 ‘Bringing together long-term remote monitoring, digital
epidemiology and continuous disease monitoring’, and
‘developing measures to collect, link, store and share ap-
propriate data and outcomes for MLTC-M, particularly fo-
cusing on longitudinal aspects including continuous disease
monitoring’ are included as aims that will drive advances in
our understanding of MLTC-M, as stated in the UK’s cross-
funder multimorbidity research framework.12
Many research studies have successfully used smart-
phones to track symptoms longitudinally for specific health
conditions, such as chronic pain,13 rheumatoid arthritis,14
heart failure 15 and COVID-19.16 Smartwatches provide a
similarly exciting opportunity for health research, as they
combine the ability to self-report symptoms on a wrist-worn
touchscreen with passive collection of sensor data,
including heart rate and movement.17,18 Remote sensor and
monitoring technologies, including smartwatches, can re-
cord variations in individual’s condition over time, and
healthcare professionals can use this information for risk
assessment and informed clinical decisions.19
An important challenge for MLTC-M using any con-
sumer device, however, is designing a flexible data col-
lection system that can be tailored to measuring symptoms
relevant to the specific combination of conditions an in-
dividual participant may have. Asking irrelevant questions
is likely to increase attrition and drop-out.20 There are no
published studies where people with multiple long-term
conditions used consumer smartwatches to collect multiple
symptoms over time. It is thus important to understand
whether people living with MLTC-M would be willing and
able to track symptoms through time, given their greater
burden of disease and treatment (Mair, 2014), and possible
lower digital literacy among some older patients (Oh et al.,
2021).
Therefore, the aim of this study was to investigate
longitudinal user engagement with a smartwatch applica-
tion, collecting daily survey questions and active tasks over
90 days, in people living with MLTC-M. Specifically, the
objectives of the study were to:
1. Describe engagement patterns over time by assessing
(a) the completeness of scheduled questions and
active tasks and (b) frequency and patterns of un-
scheduled survey and active task responses;
2. stratify engagement patterns by age, gender, number
of disease areas and question type (generic or organ-
specific), and by time of day and week;
3. survey participants’ views of the acceptability and
usability of the smartwatch for data collection.
Methods
‘Watch Your Steps’ was a prospective observational
smartwatch study, conducted by the University of Man-
chester in partnership with Google Fit Research. The study
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asked people living with MLTC-M to complete multiple
daily and weekly questions and active tasks over 90 days. In
this section, we first describe the co-design workshop then
the data collection system, participant recruitment and data
collection procedures before describing our analysis
methods to answer each of the three study objectives.
App co-design workshop with patients, clinicians
and researchers
The research team from the University of Manchester
specified an initial data collection structure that would in-
clude a series of core data items for all participants, com-
plemented with a series of more specific symptoms that
would vary according to the disease areas of participants’
different long-term conditions. At a local venue in Greater
Manchester, a two-hour multi-stakeholder workshop was
attended by people living with MLTC-M (n = 6), clinicians
(n = 6) and researchers (n = 6). People living with MLTC-M
were recruited from the local patient and public involvement
and engagement group. Clinicians and researchers were
representatives of the local clinical and research teams from
where participants of the Watch Your Steps study were re-
cruited. The workshop established a consensus on what
generic and organ-specific symptom questions to collect and
how often, while balancing the relevance of symptom
questions against participants’ burden of symptom reporting.
Table S1 (in supplementary material) displays the final list of
data items and when and how often they were prompted.
App development and testing
The Google Fit Research team developed the Watch Your
Steps study app. Each study participant was prompted (by a
notification with an audible vibration) at the specified day/
time to complete one of three smartwatch tasks: (i) core
symptom questions (for all participants), (ii) organ-specific
questions (based on participants’ disease areas) and (iii)
active tasks, including a sit-to-stand test, walk test and tap test
(see Table S2 of supplementary materials). Questions re-
mained active on the watch face for three hours for daily
questions and for 24 hours for weekly questions. For ex-
ample, a participant received a prompt on their smartwatch to
answer the pain level question at 18:00, which then remained
active until 21:00. In addition to when prompted, participants
could answer any question at any time through the app menu,
including those not required for their baseline disease areas.
Fossil Sport smartwatches were pre-loaded with the
study app (Figure 1) and loaned to participants for the
duration of the study. Each watch had a unique code as-
signed to the study participant. Participants were also
provided with a mobile broadband router (or Mi-Fi device).
They were advised to dock their watch each night for
charging, at which time the encrypted study data would also
be transmitted securely. This information along with
guidance on data collection via watch face and contact
details for troubleshooting support were included in the user
guide (annexure S1: supplementary materials).
Responses to questions were collected either as a nu-
merical value 0–10 by moving a selector around a radial
interface (Figure 1(a)–(c)), or as categorical responses
(Figure 1(d)–(e)). Questions with a numeric rating scale
included word anchors at 0 and 10 (e.g. no pain and worst
possible pain; supplementary Table S1) and a dynamic
emoticon that varied to illustrate ‘good’ vs ‘bad’ responses
(Figure 1(b)). The smartwatch also collected continuous
passive data on physical activity and heart rate from its
gyroscope, accelerometer and photoplethysmography (de-
tects volumetric changes in blood) sensors.
The smartwatch did not support any other application in
addition to the Watch Your Steps data collection app, except
displaying the date and time. During the study period, par-
ticipants did not receive any feedback or summary of their
data via the watch face. However, we shared personalised
graphical summaries of the data upon study completion.
Participant eligibility and recruitment
Eligibility criteria. Adults (aged 18 and above) with more than
one clinician-diagnosed long-term condition were eligible
to take part in the study if they were willing to wear a
smartwatch for 90 days and were able to understand written
instructions in English. We excluded bedbound patients and
those who lacked capacity to provide informed consent.
Recruitment. Participants were recruited from rheumatol-
ogy, dermatology, elderly care, respiratory and renal
medicine outpatient departments at a local teaching hos-
pital; one community general practice surgery in Greater
Manchester; and two local patient and public involvement
and engagement groups.
Potential participants either self-referred in response to
study flyers or posters displayed in waiting areas or sent via
the patient and public involvement and engagement groups,
or were encouraged by clinicians to contact the research
team. Interested participants were emailed the participant
information sheet and the University of Manchester privacy
notice (http://documents.manchester.ac.uk/display.aspx?
DocID=37095). A researcher was also available in the
waiting area on selected days to facilitate recruitment.
Potential participants were screened by telephone for
eligibility by a researcher using a screening proforma. El-
igible participants were invited to an on-boarding event,
where they were asked to sign the consent form, instructed
how to use their smartwatch and provided with a copy of the
app user guide. Recruitment and on-boarding were done
remotely via telephone or Zoom following the onset of the
COVID-19 pandemic.
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Data collection
Data collection was started in December 2019 and continued
during the COVID-19 pandemic and completed in September
2020. As part of their on-boarding, participants completed a
web-based baseline questionnaire to record their demo-
graphics and their existing use of health apps (annexure S2:
supplementary materials). Participants also completed an
introductory questionnaire on the study smartwatch about
disease areas and employment status to guide subsequent
questions (see Table S1: supplementary materials).
Participants were prompted to complete daily and weekly
smartwatch surveys and active tasks as described above.
Upon completion of the 90 days’ study period or withdrawal
from the study (if they had an experience of more than one
day of data collection), study participants were invited to
complete a web-based end-of-study questionnaire to assess
acceptability and usability of the smartwatch data collection
(annexure S3: supplementary materials).
Data analysis
Responses were classified as either scheduled or un-
scheduled. Completion of scheduled responses occurred
when they were provided for ‘the question at the right time’,
that is, generic or organ-specific questions or tasks were
answered within the allocated time window. For a given
interval, a participant’s completion rate was the number of
responses received to unique scheduled tasks, divided by
the total number of tasks scheduled during that period. So,
for example, consider a hypothetical participant who re-
ported having a joint condition and a heart condition. On a
given Monday during the study period, they would be asked
to answer 14 ‘generic’ questions, one active test (sit-to-
stand), plus seven additional organ-specific questions (in-
cluding stiffness, pain and breathlessness), amounting to 22
scheduled tasks (figure 2). The completion rate for that day
is the proportion of those 22 tasks (21 questions and 1 active
test) for which at least one response was received within the
respective time windows.
Users could also provide responses that were either to the
‘wrong questions’ (not relevant to their baseline health
conditions) or at the ‘wrong time’ (outside the scheduled
time window) or both, by accessing these tasks via the in-
app menu. The daily completion rate does not capture such
unscheduled or additional responses. The distribution of the
frequency and timing of additional tasks for each participant
were summarised via density plots and dot plots.
Objectives 1 and 2: Comparing engagement
patterns over time, overall and compared
between groups
Engagement patterns over time are represented graphically
via longitudinal line graphs of daily completion rate, aligned
Figure 1. Images of the smartwatch face showing different input methods and their steps. (a) Radial interface for anxiety (a symptom
question with a numerical rating scale response). (b) Moving selector on the radial interface showing a dynamic emoticon. (c)
Submitting response by tapping the tick mark. (d) Wording of the appetite question (a symptom with a categorical response). (e)
Selection of a categorical response option. (f) Submitting response by tapping the tick mark.
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on the first day of each participant’s involvement, to provide
an idea of attrition or dropout throughout the 90 days. The
trajectory of these lines – their peaks and troughs – offer an
indication of how many scheduled responses the participants
provided on each day of the study, while allowing for dif-
ferent participants answering different questions according to
their respective health conditions. The distribution of overall
completion rates is summarised via dot plots.
Grouping these visualisations by participants’ sex, age
group, number of disease areas and employment status, we
can see visually if there appear to be systematic differences
in how different groups engaged with the study.
Objective 3: Acceptability and usability of the app
The responses collected through web-based end-of-study
questionnaire were analysed descriptively and presented as
frequencies and percentages.
Ethical approval
The study received a favourable NHS REC opinion and
HRA approval (19/WM/0307).
Results
General characteristics of the study participants
Out of 62 people screened for eligibility, 85% (n = 53)
consented to take part in the study. Around half were male
(n = 26; 49%) and the majority had a white ethnic back-
ground (n = 45; 85%) (Table 1). Just over half were aged
between 50 and 69 (n = 28; 52%); most were employed (n =
31; 58%); and the majority reported three or fewer disease
areas (n = 46; 87%). ‘Bone, joint and muscle’ was the most
common disease area (68%) followed by ‘skin’ (45%) and
‘heart and lung’ (40%). Eight people formally withdrew
from the study before 90 days due to health problems,
perceived side-effects of smartwatch use (e.g. rash) or other
reasons.
User engagement patterns
Completion of scheduled questions. Figure 3 shows the daily
completion rate over time for all participants. About a third
of participants engaged with the app nearly every day of the
study period, completing at least one survey response in a
day. Over three quarters of the participants (n = 41; 77%)
stayed in the study by providing data throughout the study
period, albeit sometimes at low rates and sporadic intervals.
The overall completion rate of symptom questions was 45%
(interquartile range (IQR) 23–67%) (see figure 6).
Figure 4 shows the marginal distributions: average en-
gagement per participant over the whole study period. A
lower average engagement could be attributed to consis-
tently fewer responses provided each day, or periods of high
engagement punctuated by gaps with zero responses.
Completion of scheduled active tasks. Participants had 13
unique opportunities to complete each active task – once for
each week of the study. None of the participants completed
all assigned active tasks; the tap test was completed more
often (median 5 out of 13 completed; IQR 2–8) than the sit-
to-stand (median 4; IQR 2–7) or walk test (median 3, IQR
2–5).
Figure 2. Daily burden of data collection of a hypothetical participant. For this participant, the number of daily scheduled questions is
constant at 21 per day with three additional active tests through the week, that is, sit-to-stand test onMonday, walk test onWednesday
and tap test on Saturday, totalling 150 scheduled tasks per week.
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Engagement with unscheduled tasks. With no upper bound for
the possible number of unscheduled responses a user might
provide, there was a greater variation among participants.
Figure 5 shows the frequency distribution of unscheduled
responses. All participants (except one who did not con-
tribute any data) provided at least one unscheduled re-
sponse, with two participants providing more than a
thousand unscheduled responses in the 90-day period.
‘Additional or unscheduled active tasks’ occurred when
participants completed tasks outside the specified 24-hour
window. These unscheduled responses were distributed
uniformly through the week: there was no particular day that
participants appeared to prefer over the ones scheduled.
Stratified user engagement patterns
Engagement patterns were similar when grouped according
to baseline characteristics of the participants (Figure S1:
supplementary material). It appeared that many of the most
consistently highly engaged participants were over 60 years
old, whereas under-30s tended to be either less engaged or
less consistently engaged (Figure S1a: supplementary
material). People with more than three disease areas were
among the most engaged (Figure S1d: supplementary
material). Engagement was not different between genders
(Figure S2: supplementary materials). There was no ob-
vious difference in engagement pattern between those who




Gender Male 26 (49)
Female 26 (49)
Prefer not to say 1 (2)






Ethnicity White 45 (85)
Mixed or non-white 8 (15)
Employed Yes 31 (58)
No 22 (42)





Pre-specified list of disease areas Bone, joint and muscle (e.g. arthritis, neck/back pain,
chronic pain)
36 (68)
Skin (e.g. psoriasis, eczema) 24 (45)
Heart and lung (e.g. angina, heart failure, COPD/asthma) 21 (40)
Stomach and bowel (e.g. persistent nausea and vomiting,
inflammatory bowel disease)
18 (34)
Kidney (e.g. chronic kidney disease) 8 (15)
Endocrine (e.g. diabetes, thyroid disorders) 18 (34)
Mental health (e.g. anxiety, depression, schizophrenia) 20 (38)
Neurological (e.g. epilepsy, MS, Parkinson) 8 (15)
Do you own any activity monitoring devices? Yes 22 (41)
No 31 (59)
Do you use any smartphone health/well-being apps? Yes 25 (47)
No 28 (53)






aAll participants were confirmed as having two or more LTCs during eligibility screening. The number of pre-specified disease areas refers only to the
specific, named organ systems listed here.
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Figure 3. Proportions of scheduled daily questions answered by each participant on each day of the three-month study period. Daily
completion rate is encoded by the height and colour: tall, bright yellow segments represent days with nearly 100% of scheduled
questions answered by a participant that day. Low and dark blue areas represent low completion, with a flat line indicating zero
scheduled responses on a given day. Eight users formally dropped out of the study at which point their line showed as a dotted line. The y-
axis labels are four-digit participant identifiers.
Figure 4. Distribution of average daily completion rate of scheduled questions among the participants over the whole 90-day study
period. Each dot represents one participant.
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Figure 5. Distribution of the number of unscheduled responses received from each participant over the whole 90-day study period.
Each dot represents one participant. Presented on a logarithmic scale.
Figure 6. Average proportions of scheduled survey questions completed on time over the study period.
Table 2. Average completion of scheduled survey questions on time per disease area.
Disease area Total participants (n)a Median (IQR) (%)
Bone, joint and muscle 35 45 (24–66)
Skin 22 48 (40–69)
Heart and lung 22 53 (28–79)
Stomach and bowel 20 47 (26–67)
Kidney 7 81 (57–84)
Mental health 20 33 (17–61)
aResults represent participants who reported the presence of that disease area, irrespective of other conditions. As this is a study of MLTC-M, participants
could be included in more than one group.
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use smartphone health/well-being apps (n = 25; median
46%; IQR 23–64%) and those who do not use any
smartphone-based health/well-being apps (n = 28; median
43%; IQR 23–67%). Ridge plots of engagement, stratified
by prior use of health/ well-being apps, are included in the
online supplementary materials.
Medians and IQRs of completion rates of scheduled
survey questions are provided in figure 6.
Across different disease areas, we found that people
with kidney conditions had the highest completion rate
(81%; IQR 57–84%) and people with a mental health
condition had the lowest completion rate (33%; IQR 17–
61%) (see table 2). Ridge plots of engagement, stratified by
disease areas, are included in the online supplementary
materials.
While responses to scheduled questions and active tasks
were distributed throughout the day, unscheduled responses
were reported more commonly in the evening (Figure 7).
There was no clear difference in the number of un-
scheduled or additional tasks completed by male versus
female participants, nor among those with different numbers
of disease areas. But unemployed and older participants
were more likely to provide a large number of unscheduled
responses compared to employed or younger people, re-
spectively (Figure S3: supplementary materials).
Usability and acceptability of smartwatch
data collection
Out of 53 invited study participants, 49 self-completed the
end-of-study questionnaire. Figure 8 shows that the ma-
jority of those (strongly) agreed that it was easy to navigate
the smartwatch study app (n = 42; 86%), while slightly more
females (92%) agreed to this than males (80%). They found
it easy to understand the response scale (n = 42; 86%) and to
enter symptoms using the smartwatch (n = 39; 80%). In
Figure 7. Marginal distribution of responses by time of day. Responses are divided into ‘prompted’ (relevant to a participant’s baseline
conditions) and ‘unprompted’ (additional questions the participants answered through the app). Untimely responses are included.
Figure 8. Key usability aspects of the smartwatch study app. Frequency, timing and type of symptom questions.
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terms of ease of understanding and entering answer to the
response scale, there was no significant difference between
groups across genders and age groups.
Most participants (n = 31; 63%) did not consider data
collection tasks disruptive, while slightly more participants
with greater disease burden (≥3 disease areas) (5 out of 21;
24%) found it disruptive than participants with lesser dis-
ease burden (3 out of 30; 10%). However, almost all (n = 48;
98%) stating that the smartwatch did not stop them from
going about their normal daily activities (figure 8).
Most study participants (63%; n = 31) thought the total
number of questions per day was about right. More than half
of the study participants found data collection at five time
points per day ‘about right’ (n = 29; 59%) while around a
third (n = 15, 31%) felt that it was ‘a bit too high’.
Among those who responded to the questions related to
the timings of symptom questions, more people found 12
noon questions convenient to answer (62%), followed by
08:00 (61%), 16:00 (56%), 20:00 (53%) and 18:00 (40%)
hours. Moreover, nearly half of the study participants (n =
22; 45%) said that they would like to report their symptoms
after 20:00 hours.
Figure 9 shows that, of the seven core symptoms, fatigue
was perceived by most people (n = 44; 90%) as a useful
symptom to track followed by pain (n = 38; 78%) and sleep
(n = 37; 75%).
Discussion
Key findings
We have demonstrated that using a smartwatch for health
data collection is feasible and acceptable for individuals
living with MLTC-M over a 90-day period. Across all
participants, we found a median completion rate of
scheduled tasks of 45% (IQR 23–67%), with the highest rate
among 70–79 year-olds (73% completion (IQR 55–82%)).
Patterns of engagement were heterogeneous; older partic-
ipants and participants with more than three disease areas
were among the most engaged. Despite the high burden of
diseases and symptoms and number of questions asked per
day, individuals with MLTC-M mostly engaged with the
smartwatch data collection system throughout the 90-day
period. Whether this level of engagement is acceptable for
future research will, of course, depend on what research
question is being addressed. Overall, we were pleasantly
surprised that the engagement was so high given we were
ambitious in asking for over 20 responses per day.
Participants found the app easy to navigate, interact with
and understand. Themajority felt that the frequency (5–6 times
per day) and volume of tasks (14–22 tasks per day) was ‘about
right’. Participants reported that 20:00 was the most conve-
nient time at which to be prompted. The same was reflected in
the completion rate being highest at 20:00, both for scheduled
and unscheduled responses. Though 20:00 appeared to be a
suitable time for prompts on the smartwatch, future data
collection system should consider offering a customisation
feature to participants about selecting type and timing of
prompts that suit their self-reporting preferences, assuming
that aligns with the data requirements for the study (21).
Fatigue, pain and sleep disturbance were rated as the most
useful symptoms to track by participants, and active tasks were
less likely than survey questions to be completed as scheduled.
Strengths and limitations
Consumer technology has been recognised as an opportu-
nity for MLTC-M health research, yet most digital health
studies were conducted in younger or healthier people.22 To
our knowledge, this was the first study to examine the use of
a smartwatch app designed for people with multiple long-
term conditions. We designed a data collection system with
key stakeholders to find a balance between utility and re-
porting burden of multiple daily symptoms which might
have helped to sustain engagement during the study. Fur-
thermore, we designed the semi-configurable data collection
system using a model of ‘core data’ and ‘data by disease
area’, which contrasted with studies that typically asked
only disease-specific questions matched to clear recruitment
criteria for those diseases.23
The study also had some limitations. Study participants
self-selected to participate and may therefore not be rep-
resentative of all patients living with MLTC-M. This mo-
tivated cohort may have generated more generous
engagement patterns compared to an unselected cohort. The
age distribution was younger than we might see in unse-
lected MLTC-M populations.24,25 Nonetheless, the results
indicated that a larger cohort of people might be willing to
participate in a smartwatch study.
The study duration was 90 days, and inferences about
engagement patterns beyond this time point cannot be
made. Engagement with mobile health (mHealth) appli-
cations tends to decay with time, and the potential utility of
symptom tracking in both clinical and research contexts
might require engagement for a longer interval, depending
on the study question.26
Figure 9. Symptoms participants considered useful to track.
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Previous publications have highlighted that incorporat-
ing a mechanism for feedback to users about inputted data
can help sustain engagement.27–29 The presence of real-time
feedback to participants would potentially have improved
their engagement in this study.30 Motivation may also have
been greater if there has been a clear scientific question
being addressed that was important to the participants.28
Relation to previous work
Assessments of engagement in previous smartwatch studies
relate broadly to adherence with either active data collection
or passive monitoring for a single long-term condition.
Approaches to defining engagement with active data col-
lection are variable, which makes directly comparing re-
ported rates of engagement challenging.30,31 Whilst we had
a relatively high burden of daily questions and tasks with no
feedback on the watch face, we maintained reasonable
levels of engagement compared to other studies.18,30,31 The
patterns of engagement were similar to our previous
smartwatch study in patients with knee osteoarthritis, de-
spite the higher number of questions per day in this study
and the difference in populations (MLTC-M versus knee
osteoarthritis).18 Elm et al. studied 51 participants with
Parkinson’s Disease, requiring three patient-reported out-
come measures to be entered via an app per day.32 By three
months, they reported around 45% completion, a figure
similar to our MLTC-M population who were responding to
around 20 questions per day. The group with highest en-
gagement was older than average in their study, similar to
our finding. However, in several web- and smartphone-
based studies, as reported in a systematic review, engage-
ment was lower in older people.31 Midaglia et al, in their
study of 75 individuals aged between 20 and 57 years with
multiple sclerosis, defined engagement to scheduled active
tasks as the proportion of study weeks with at least 3 days of
complete tasks. They observed an overall adherence to
active tasks of 70% and remained broadly stable over the
24-week study period.33
Implications for future research
In the present study, prompts were personalised at the level
of the disease area. Future digital health studies could be
strengthened by more flexible and personalised data col-
lection schedules reflecting the specific conditions affecting
an individual, the symptoms that they perceive as being a
priority and their lifestyles. We should consider however
that increased heterogeneity in responses will complicate
comparison between participants. Therefore, these two
priorities ought to be balanced carefully depending upon the
context and scientific question.
For researchers planning future digital health studies, we
hope that our findings will give an indication of the expected
levels and patterns of engagement in a cohort of people
living with MLTC-M. Our findings will also guide future
optimal scheduling of data collection. Greater engagement
could be achieved by adding incentives such as feedback of
tracked symptoms. In the current study, the sole purpose of
data collection was to support research. In the future, in-
tegrating patient-reported symptoms (+/- sensor data) from
smartwatches into electronic health records could also
support clinical care: visual summaries of longitudinal
tracked symptoms can provide a clearer picture of disease
for better shared decision making.14,34
Conclusion
This study demonstrates that it is feasible for people living
with MLTC-M to report multiple symptoms per day over
several months. It suggests that participant engagement can
be as good as in other mobile health studies that recruited
people living with a single health conditions, and which had
a lower data entry burden per day. In the future, integrating
patient-reported symptoms (+/- sensor data) from smart-
watches into electronic health records could also support
clinical care by providing visual summaries of longitudinal
tracked symptoms for better shared decision making. The
study provides evidence that digital epidemiology using
personal devices might indeed deliver against its promise12
for MLTC-M research.
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